← Back to Search

Dynamic Contrast-Enhanced MRI for Eye Cancer

N/A
Waitlist Available
Led By Michael Knopp
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Exposure to gadolinium-based contrast agents increases the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or severe renal dysfunction; therefore, patients with the following conditions are excluded from the study: Acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73 m^2), Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative liver transplantation period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will help researchers learn more about how best to use a new MRI technique to evaluate diseases of the eye and eye socket.

Who is the study for?
This trial is for individuals who need further diagnosis or monitoring of an orbital mass (eye or eye socket tumor) and can return for follow-up visits. They must be able to give informed consent. It's not suitable for those with severe kidney issues, certain metal implants, allergies to metals or contrast agents, claustrophobia, pregnant women, prisoners, or anyone under conditions that would interfere with MRI.
What is being tested?
The study tests a new imaging method using dynamic contrast-enhanced MRI to improve the evaluation of diseases in the eye and orbit. It aims to provide detailed images and information about blood circulation in these areas which may help determine if the tumor could spread.
What are the potential side effects?
While this study involves imaging rather than medication, there are still risks associated with MRI scans such as discomfort from lying still during the procedure. There's also a small risk of allergic reaction to the contrast dye used in dynamic MRIs.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidneys work well and I don't have severe renal insufficiency.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Diagnosis of benign vs. malignant lesions using DCE-MRI
Improved characterization of different malignant tumor types

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dynamic contrast-enhanced MRIExperimental Treatment1 Intervention
Patients undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)

Find a Location

Who is running the clinical trial?

University of CincinnatiLead Sponsor
436 Previous Clinical Trials
635,282 Total Patients Enrolled
Ohio State University Comprehensive Cancer CenterLead Sponsor
340 Previous Clinical Trials
294,175 Total Patients Enrolled
Michael KnoppPrincipal InvestigatorOhio State University Comprehensive Cancer Center

Media Library

dynamic contrast-enhanced MRI Clinical Trial Eligibility Overview. Trial Name: NCT01653080 — N/A
Retinoblastoma Research Study Groups: Dynamic contrast-enhanced MRI
Retinoblastoma Clinical Trial 2023: dynamic contrast-enhanced MRI Highlights & Side Effects. Trial Name: NCT01653080 — N/A
dynamic contrast-enhanced MRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT01653080 — N/A
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top